Teva Licenses Xenon Pharmaceuticals’ Pain Drug XEN402 as Part of New Strategic Plan
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 12 (Table of Contents)
Published: 31 Dec-2012
DOI: 10.3833/pdr.v2012.i12.1863 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In line with its strategy of building a branded drugs pipeline focused on respiratory and CNS diseases, Teva Pharmaceutical industries has licensed global rights to develop and commercialise Xenon Pharmaceuticals’ clinical-stage pain drug XEN402...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS